Aster DM Healthcare Ltd (ASTERDM) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Aster DM Healthcare reported strong Q1 FY26 results, with revenue up 8% YoY, operating EBITDA up 21%, and PAT up 22%.
- The Kerala cluster showed recovery with 5% YoY revenue growth, driven by stabilized leadership and improved medical value travel (MVT).
- ARPOB crossed INR 50,000 for the first time, driven by a shift towards high-value businesses, specialty mix enhancement, and a 4% reduction in ALOS.
- Oncology's revenue share increased to 11%, reflecting its growing importance in the clinical strategy.
- The merger with QCIL is progressing, with key approvals secured and a strategic share swap completed.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.